Understand the source comparison
Best Peptides for Heart Disease Prevention: Mechanism Comparison
Thymalin Thymic epithelial regeneration, T-regulatory cell production Reduces systemic inflammation (inflammaging), stabilizes atherosclerotic plaques 5–10mg subcutaneous, 2x weekly IL-6 reduction 18–22%, Treg count increase 28–34% Addresses immune senescence
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic epithelial regeneration, T-regulatory cell production
- Reduces systemic inflammation (inflammaging), stabilizes atherosclerotic plaques
- 5–10mg subcutaneous, 2x weekly
- IL-6 reduction 18–22%, Treg count increase 28–34%
- Addresses immune senescence driving chronic vascular inflammation. Upstream prevention
- BPC-157
- VEGF receptor upregulation, eNOS stabilization, angiogenesis
- Restores endothelial nitric oxide function, promotes collateral vessel formation
- 200–500 mcg subcutaneous daily
- eNOS expression +28%, capillary density +40% in ischemic tissue
- Repairs endothelial dysfunction and enhances vascular repair capacity at the tissue level
- GHK-Cu
- NF-kappa-B suppression, SOD upregulation, copper-dependent gene modulation
- Reduces oxidative stress, suppresses pro-inflammatory cytokine cascades
- 1.5–3mg oral or subcutaneous daily
- hs-CRP reduction 20–23%, TNF-alpha suppression up to 47%
- Direct anti-inflammatory and antioxidant action. Prevents oxidative LDL modification
- Hexarelin
- Growth hormone secretagogue, cardioprotective GHS-R1a activation
- Myocardial protection, reduces apoptosis in ischemic heart tissue
- 100–200 mcg subcutaneous, 1–2x daily
- Left ventricular ejection fraction improvement in animal models
- GH-independent cardioprotection. Mechanistically distinct from other GH secretagogues
- Cartalax
- Bioregulator targeting vascular smooth muscle, telomere stabilization
- Prevents arterial stiffening, supports endothelial regeneration
- 10–20mg oral, daily
- Pulse wave velocity reduction (arterial compliance marker)
- Emerging evidence for vascular aging intervention. Less direct inflammatory action than GHK-Cu